| Autor: |
Chester L. Drum, Warren K. Y. Tan, Siew‐Pang Chan, Leroy S. Pakkiri, Jenny P. C. Chong, Oi‐Wah Liew, Tze‐Pin Ng, Lieng‐Hsi Ling, David Sim, Kui‐Toh G. Leong, Daniel P. S. Yeo, Hean‐Yee Ong, Fazlur Jaufeerally, Raymond C. C. Wong, Ping Chai, Adrian F. Low, Pia Davidsson, Mathias Liljeblad, Ann‐Sofi Söderling, Li‐Ming Gan, Ratan V. Bhat, Kristy Purnamawati, Carolyn S. P. Lam, A. Mark Richards |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 6 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.117.005586 |
| Popis: |
BackgroundThymosin beta‐4 (TB4) is an X‐linked gene product with cardioprotective properties. Little is known about plasma concentration of TB4 in heart failure (HF), and its relationship with other cardiovascular biomarkers. We sought to evaluate circulating TB4 in HF patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction compared to non‐HF controls. Methods and ResultsTB4 was measured using a liquid chromatography and mass spectrometry assay in age‐ and sex‐matched HFpEF (n=219), HFrEF (n=219) patients, and controls (n=219) from a prospective nationwide study. Additionally, a 92‐marker multiplex proximity extension assay was measured to identify biomarker covariates. Compared with controls, plasma TB4 was elevated in HFpEF (985 [421–1723] ng/mL versus 1401 [720–2379] ng/mL, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text